drugset / Trial / NCT03819101
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Phase 3
Recruiting
1210 enrolled
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France · collab
RandomizedFactorialOpen-labelTreatment
Summary
This is a 2x2 factorial randomized, multicenter, international, open phase III trial. The primary objective is to evaluate the benefit of acetylsalicylic acid and atorvastatin on overall survival (OS) (main endpoint) for patients with castrate-resistant prostate cancer starting first line treatment for CRPC
Timeline
- Start
- 2019-06-06
- Primary completion
- 2042-03
- Completion
- 2042-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 100 mg | — |
| Subject | Atorvastatin | Small molecule | 80 mg | — |